Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

939 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kröger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M. Casper J, et al. Among authors: freund m. J Clin Oncol. 2010 Jul 10;28(20):3344-51. doi: 10.1200/JCO.2009.23.3429. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498405
Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Junghanss C, Rathsack S, Wacke R, Weirich V, Vogel H, Drewelow B, Mueller S, Altmann S, Freund M, Lange S. Junghanss C, et al. Among authors: freund m. Biol Blood Marrow Transplant. 2012 Jul;18(7):1061-8. doi: 10.1016/j.bbmt.2011.12.522. Epub 2011 Dec 16. Biol Blood Marrow Transplant. 2012. PMID: 22182476 Free article.
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J. Ruutu T, et al. Among authors: freund m. Haematologica. 2011 Sep;96(9):1344-50. doi: 10.3324/haematol.2011.043810. Epub 2011 Jun 9. Haematologica. 2011. PMID: 21659356 Free PMC article. Clinical Trial.
Engraftment Efficiency after Intra-Bone Marrow versus Intravenous Transplantation of Bone Marrow Cells in a Canine Nonmyeloablative Dog Leukocyte Antigen-Identical Transplantation Model.
Lange S, Steder A, Killian D, Knuebel G, Sekora A, Vogel H, Lindner I, Dunkelmann S, Prall F, Murua Escobar H, Freund M, Junghanss C. Lange S, et al. Among authors: freund m. Biol Blood Marrow Transplant. 2017 Feb;23(2):247-254. doi: 10.1016/j.bbmt.2016.10.025. Epub 2016 Nov 2. Biol Blood Marrow Transplant. 2017. PMID: 27816649 Free article.
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuk F, Krüll A, Zander A; German Study-group Multiple Myeloma (DSMM). Kröger N, et al. Among authors: freund m. Bone Marrow Transplant. 2003 Jun;31(11):973-9. doi: 10.1038/sj.bmt.1704049. Bone Marrow Transplant. 2003. PMID: 12774047 Clinical Trial.
939 results